Intraocular Cytokines in Non-responders to Ranibizumab Treatment for Neovascular AMD

Sponsor
University Health Network, Toronto
Study ID
NCT02218177
Status
Completed

Conditions

  • Age Related Macular Degeneration

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Aflibercept — DRUG
    anti-VEGF treatment for wet age related macular degeneration
  • Ranibizumab — DRUG
    anti-VEGF treatment for wet age related macular degeneration
  • Combination Photodynamic Therapy — PROCEDURE
    Use of cold laser with an intravitreal injection of dexamethasone to treat wet age related macular degeneration

Study Details

The purpose of this study is to evaluate the level of cytokines (which are small proteins important in cell signalling) in eye fluid (aqueous humour) in patients with wet age related macular degeneration patients who have been treated with an injection in the eye (intravitreal injection) with a drug called ranibizumab. The level of cytokines will be compared between patients who have a good response to ranibizumab treatment and patients who are non-responsive to ranibizumab and need other forms of therapy. This knowledge will help for the future treatment and to potentially develop new medication for wet age-related macular degeneration.

Key Dates

Start date
Aug 31, 2014
Status verified
Oct 2018
Primary completion
Aug 31, 2016
Completion
Dec 31, 2016

Study Design

Enrollment
30 participants (actual)

Arms

  • Arm: Non-responders receiving aflibercept therapy
    Non-responders to ranibizumab who are now receiving aflibercept therapy
  • Arm: Non-responders receiving PDT combo therapy
    patients who are non-responders to ranibizumab who have been switched to combination photodynamic therapy (PDT)
  • Arm: Responders to ranibizumab
    Patients who are responders to ranibizumab and are continuing monthly injections.

Primary Outcome Measure

Aqueous Humour Cytokine Levels [ Time Frame: At time of Intravitreal Injection ]

Related Studies